Dr Reddy’s Laboratories will soon introduce Molnupiravir for the treatment of Covid-19

Earlier this year, the drug major entered into a non-exclusive voluntary licensing agreement with Merck Sharp Dohme (MSD) to manufacture and supply molanupiravir to India and more than 100 low and middle income countries (LMICs). (File photo/PTI)

Molanupiravir is an oral antiviral that inhibits the replication of several RNA viruses, including SARS-CoV-2.

  • PTI New Delhi
  • Last Update:December 28, 2021, 7:23 pm IS
  • What should I follow:

Reddy’s Laboratories on Tuesday said it will soon introduce antiviral drug Molnupiravir Capsules (200mg) to treat adult patients of COVID-19 across the country. The Hyderabad-based firm said it will introduce the drug in India under the brand name Molflu.

The company has received emergency-use authorization from the Drug Controller General of India (DCGI) to manufacture and market an antiviral drug to treat adult patients of COVID-19 who are at high risk of disease progression including hospitalization or death. There is risk. , Earlier this year, the drug major entered into a non-exclusive voluntary licensing agreement with Merck Sharp Dohme (MSD) to manufacture and supply molanupiravir to India and more than 100 low and middle income countries (LMICs).

“Molnupiravir is a continuation of our sustained effort since the start of the pandemic to ensure access to every possible treatment option against COVID-19 for patients in India and around the world, from mild, moderate and severe disease prevention,” Dr. Reddy’s Co-Chairman and Managing Director GV Prasad said in a statement. He said the approval to launch Molnupiravir not only as a treatment option but also as a collaborative way for Indian pharma companies to come together is a significant development.

“During the pandemic, we have sought to forge diverse collaborations and partnerships to address the medical needs of more and more patients globally,” Prasad said. In a first of its kind collaboration in the Indian pharmaceutical industry, a consortium of pharma companies led by Dr Reddy’s collaborated to jointly sponsor, supervise and monitor Phase III clinical trials in India and present their findings to a subject expert committee. Did it (SEC).

The pharmaceutical firm said that it is capable of manufacturing active pharmaceutical ingredients (APIs) as well as molnupiravir and has prepared enough capacity to ensure that it helps patients in India as well as needy populations across the world. able to do. , Molanupiravir is an oral antiviral that inhibits the replication of several RNA viruses, including SARS-CoV-2.

read all breaking news, today’s fresh news And coronavirus news Here.

,